Adani Ports and SEZ Rating- reduce; Weak performance was along expected lines
时间:2024-06-26 15:06:54 阅读(143)
APSEZ reported an expectedly weak print in Q4. Its capex plan aims to provide the path for APSEZ to (1) reach 500-mn ton port volume target by FY2025 from 350-360-mn FY2023 guidance and (2) become a transport utility with a strong logistics offering. Up-fronting of capex and fluid market conditions would make the path to 16% RoCE target for 2025 from current 11% difficult, more back-ended and less clear. We retain operational estimates and increase FV on roll-forward to Rs 735. Reduce stays, with 15X FY2023E EV/Ebitda trading valuations.
Weak end to the year on expected lines
Guidance reasonable on volumes and aggressive in terms of timing on capex
Volume guidance for FY2023 appears reasonable to us at 350-360 mn tons versus 312 mn tons in FY2022. The guidance lacks the punch on a low y-o-y base. The guidance on capex suggests a sharp jump to Rs 86 bn or more than 2X versus FY2022 levels. Key movers of the incremental
Rs 50 bn capex are warehousing (Rs 25 bn capex), Gangavaram (Rs 8 bn) and Mundra+Dhamra (Rs 12 bn). From a port perspective, the capex intensity is doubling in Mundra and Dhamra. In logistics, the focus is more on warehousing – equipment capex to build in land bought by Adani Ports last year. The up-fronting of capex and fluid market conditions imply that realisation of the business returns envisaged on the incremental capex may take time. This can impact the realisation of the 16% RoCE target by FY2025. Currently, the APSEZ portfolio operates at 11% RoCE (down 100 bps y-o-y).
1/We retain estimates and increase FV
We increase our FV to Rs 735 (from Rs 710), largely on account of six months of roll-forward and higher value for Gangavaram asset, with half of the increase negated by higher capex assumptions. Retain Reduce given punchy 15X FY2023E EV/Ebitda entry valuations.
猜你喜欢
- Mankind Pharma IPO Day 1- Issue subscribed 14%, HNIs subscribed one-third of quota
- Nifty to be positively biased above 19800; IT, Pharma, Automobiles looks positive
- Budget 2024- De-risk MSME credit inflows, boost credit access for advanced manufacturing, says Deloitte India
- Bitcoin Spot ETF- Crypto investors tracking US SEC announcements
- Nifty likely to head towards 18600 by December, Bank Nifty looks to hit 42900; buy SBI, Reliance for gains
- Nifty short-term trend positive; Q2 results, stocks under F&O ban, key things to know before market opens
- Boost for shipbuilders- Mazagon Dock zooms 4%; wins third order in 10 days
- Markets end in positive zone after volatile session; realty and banks shine even as IT and pharma struggle
- Nifty to defend 19600 or give up gains- See GIFT Nifty, FII data, crude, F&O ban, more before market opens